Finally, we tested the in-vitro activity of ibrutinib on SDF-1 induced migration in a spectrum of primary AML blasts from a wide age spectrum of adult patients and across a range of WHO AML subclasses (Table 1). Here, CXCL12 is linked to acute myeloid leukemia.